Starling Oncology, Inc. (STLN) Profit Margins
Over the twelve months to 2026-06-30, Starling Oncology, Inc. (STLN) had operating margin -4.4%, net margin -6.2%, free cash flow margin -0.6%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
STLNStarling Oncology, Inc.Follow STLN — free
—
Price chart with a free account
- Market cap
- 683.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating margin | -22.6% | -32.5% | -23.8% | -15.3% | -7.2% | -4.4% | |
| Net margin | -5.4% | 0.1% | -25.6% | -16.4% | -12.1% | -6.2% | |
| FCF margin | -17.5% | -26.6% | -12.6% | -7.7% | -5.5% | -0.6% |
USD millions · SEC XBRL
Starling Oncology, Inc. — questions
- What is Starling Oncology, Inc.'s operating margin?
- -4.4% over the twelve months to 2026-06-30.
- What is Starling Oncology, Inc.'s net profit margin?
- -6.2% over the twelve months to 2026-06-30.
Every figure on this page comes from Starling Oncology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.